Longevity Research Roundup: Interventions & Biomarkers (August 2026)
This August, we delve into new human data on GLP-1s, resistance training, novel geroprotectors, and nuanced takes on NAD+ supplementation.
# Longevity Research Roundup: Interventions & Biomarkers (August 2026)
Welcome back to the Longevity Stack weekly research roundup. This month, we're unpacking a fascinating array of new findings, from the surprising geroprotective signals of widely used GLP-1 agonists to refined insights on classic interventions like resistance training. We also highlight novel compounds showing promise in reversing biological age, and take a fresh look at the often-discussed NAD+ pathway.
Our focus remains firmly on human data or highly translational animal studies, steering clear of hyperbole and focusing on actionable intelligence for optimising your healthspan. Let's get stuck in.
Semaglutide Slows Epigenetic Ageing in HIV-Positive Adults
**What was found:** A re-analysis of a 32-week randomised trial involving 84 adults living with HIV has revealed a significant slowing of several DNA-methylation-based biological age clocks in those receiving semaglutide compared to a placebo group. While the initial trial primarily focused on weight and metabolic endpoints, this exploratory ageing-clock analysis indicated a favourable shift in biological age trajectory over the eight-month period. Participants in this study were metabolically vulnerable, suggesting a particularly strong benefit for high-risk cohorts.
**Why it matters:** This is, arguably, some of the first controlled human evidence to suggest that GLP-1 agonists, such as semaglutide, may do more than just manage weight and cardiometabolic risk; they might actively modulate epigenetic ageing. This strengthens the case for considering GLP-1 drugs as potential geroprotectors. For individuals with conditions like HIV, diabetes, or obesity – where accelerated biological ageing is common – these findings reinforce the value of prioritising GLP-1s as part of a broader healthspan strategy. Our editorial take: we've long suspected GLP-1s had broader systemic benefits, and this data begins to put some hard science behind those hunches.
**Actionable takeaway:** If you are in a high-risk cardiometabolic category, or have conditions known to accelerate biological ageing, discuss with your clinician whether a GLP-1 agonist like semaglutide could be a suitable option for not only metabolic health but also potential anti-ageing benefits. Remember to always consult a medical professional before considering any medication, especially when discussing off-label uses. /legal/disclaimer
Primary source: ScienceDaily Primary source: Livewellnews
The Sweet Spot for Strength Training: 90-120 Minutes Per Week
**What was found:** A remarkable 30-year longitudinal study, tracking approximately 147,000 adults, identified that 90–119 minutes of weekly strength training was associated with the lowest all-cause mortality. This 'sweet spot' also corresponded to a significant reduction in deaths from neurological diseases. Interestingly, both very low and very high volumes of strength training were less protective, indicating a U-shaped dose-response relationship.
**Why it matters:** This unusually long-term human data provides crucial refinement for our resistance training dose targets, complementing existing advice on VO₂max and zone-2 cardio. The strong signal for reduced neurological mortality is particularly compelling, adding further weight to the argument for muscle preservation protocols as a strategy for brain ageing and reducing neurodegenerative risks. It suggests that a modest, consistent effort can yield substantial, long-term health dividends.
**Actionable takeaway:** Aim for roughly 1.5 to 2 hours of structured resistance training per week. This could be two to three sessions, focusing on compound movements that work major muscle groups. Prioritise consistency over extreme intensity or volume.
Primary source: Maragin.org Primary source: Healthspan Action Coalition
PAI-1 Inhibition: A Novel Approach to Biological Age Reversal
**What was found:** A small clinical trial involving 20 healthy elderly adults demonstrated that four months of oral TM5614, a plasminogen activator inhibitor-1 (PAI-1) inhibitor, reversed several composite biological age markers by an average of 2–3 years compared to baseline. While the study size is small and long-term follow-up is pending, it provides a compelling proof-of-concept for targeting PAI-1 as an ageing pathway in humans.
**Why it matters:** PAI-1 plays a critical role in the senescence-associated secretory phenotype (SASP), thrombosis, and fibrosis – all hallmarks of ageing. Genetic and animal studies have consistently linked elevated PAI-1 levels with accelerated ageing and reduced lifespan. TM5614 is one of the first PAI-1 targeting agents to show measurable biological age reversal in humans, positioning it as a promising candidate for a new class of geroprotective drugs. This opens an exciting new axis for intervention, distinct from the more commonly discussed GLP-1 or mTOR pathways, by modulating senescence and fibrinolytic systems. /legal/disclaimer
**Actionable takeaway:** While TM5614 is not readily available, this research highlights the importance of understanding and potentially managing PAI-1 levels, especially as we age. Look for emerging research on natural compounds or lifestyle interventions that might influence PAI-1 expression, and continue to manage cardiovascular risk factors that can elevate PAI-1.
FAXAge: Fasting & Exercise Combo Trial for Ageing
**What was found:** GeroScience recently announced the study protocol for FAXAge, a new randomised, controlled trial designed to investigate whether a combined regimen of structured fasting and exercise can slow biological ageing and improve multi-system ageing markers in humans. The protocol will include various intermittent fasting schedules and exercise interventions, measuring outcomes such as methylation clocks, metabolic markers, inflammation, and functional assessments. The trial is designed to be sufficiently powered to detect meaningful changes in biological age clocks.
**Why it matters:** This study is a significant step beyond observational data, moving into controlled interventional testing of a lifestyle 'stack' that many longevity enthusiasts already practice. If successful, FAXAge could provide quantitative effect sizes for established interventions like time-restricted eating and structured training. This will offer a valuable benchmark to compare the efficacy of behavioural interventions against small-molecule geroprotectors on the same biological ageing clocks. Our hope is it will provide clarity on the minimum effective doses for these synergistic interventions, complementing our own healthspan foundation protocol.
**Actionable takeaway:** While awaiting the FAXAge results, consider incorporating time-restricted eating and regular exercise into your routine if you haven't already. These are well-established health-promoting behaviours, and this trial aims to quantify their impact on biological ageing. There's little downside and potentially significant upside.
Piceatannol: A Next-Gen Polyphenol with Senolytic Potential
**What was found:** In ageing mice models, chronic administration of piceatannol, a polyphenol structurally related to resveratrol, led to improvements in motor coordination and spatial memory. Importantly, it also reduced senescent cell burden and lowered pro-inflammatory protein levels in kidney and heart tissues, indicating potential senolytic or senomorphic activity. Early human data from a small trial (10 mg/day) showed improved skin hydration and reduced wrinkles, alongside a good safety profile, though systemic ageing endpoints were not assessed.
**Why it matters:** Piceatannol appears to possess superior senescence-modulating and anti-inflammatory properties compared to its cousin, resveratrol, positioning it as a promising 'next-generation' geroprotective supplement. The reduction in senescent cells in key organs like the kidney and heart is particularly noteworthy, given their central role in age-related morbidity. This makes piceatannol a logical candidate for inclusion in comprehensive stacks alongside other longevity compounds such as spermidine or urolithin A, once further human evidence emerges. /legal/disclaimer
**Actionable takeaway:** Piceatannol is an intriguing compound, but human data on systemic ageing effects are still nascent. If you're experimenting with novel polyphenols, ensure you source from reputable suppliers and follow dosage guidelines. Consider it a 'watch this space' rather than a 'must-have' for now.
AI-Driven Organ Ageing Map: NAD+ & ATM Kinase
**What was found:** An AI-powered systems-biology study has created an atlas of ageing across 17 organs, identifying organ-specific patterns of gene expression and pathway decline. Crucially, it found that the NAD+ pathway's responsiveness to intervention may vary significantly between organs, challenging the notion of a uniform, global NAD+ decline with age. The research also pinpointed ATM kinase as a central molecular switch for cell-cycle arrest in response to damage, suggesting its role as a key regulator of senescence and ageing.
**Why it matters:** These organ-specific NAD+ findings help explain why human trials of NR or NMN show tissue-selective effects and why whole-blood NAD+ levels may not dramatically decline with age in all individuals – a point we discuss further below. The identification of ATM kinase as a central regulator offers a new potential drug target for modulating senescence, distinct from existing p16/p21-centric strategies. This work beautifully illustrates the increasing power of AI-driven 'omics' approaches in identifying precise, organ-specific targets for future geroprotectors.
**Actionable takeaway:** Recognise that ageing is a highly heterogeneous process, even within different organs of the same individual. Future longevity interventions may become increasingly personalised and organ-specific. Continue to support general cellular health through robust mitochondrial optimisation protocols.
Primary source: YouTube (Weekly longevity news video)
Long-Lived Families & Anti-Inflammatory Genes
**What was found:** Research into families renowned for exceptional longevity has identified rare genetic variants associated with better health outcomes and extended survival. One particularly noteworthy mutation appears to temper systemic inflammation, potentially delaying the onset of age-related diseases and extending healthspan. The study supports a polygenic view of longevity, where multiple small-effect variants collectively influence immune and inflammatory ageing.
**Why it matters:** This provides compelling human genetic evidence that chronic, low-grade inflammation ('inflammaging') is not merely a correlate of ageing but a causal factor in determining healthy ageing trajectories. The identified variant offers a template for potential drug development: mimicking its functional impact could lead to novel inflammaging-targeted geroprotectors. From a practical perspective, it strongly corroborates the importance of aggressively managing low-grade inflammation (e.g., via markers like hs-CRP, IL-6, TNF) as a central pillar of healthspan optimisation. Think quality sleep, managing stress, and a diet rich in anti-inflammatory foods.
**Actionable takeaway:** Focus on lifestyle interventions known to reduce systemic inflammation: a nutrient-dense, plant-rich diet; adequate sleep; stress management; and regular exercise. Consider periodic inflammatory marker checks with your GP if you have concerns.
Modified Mediterranean-Style Diet: Low Protein, Balanced Methionine
**What was found:** An ageing mouse cohort fed a modified Mediterranean-style diet, characterised by low overall protein and carefully tuned methionine intake (primarily from plant and fish sources), showed impressive results. These mice exhibited increased healthspan, reduced body fat, and significantly lower frailty scores compared to control groups on standard diets. The diet carefully limited methionine-rich foods like eggs, red meat, and dairy, without inducing frank protein deficiency.
**Why it matters:** This study adds substantial weight to the protein and methionine restriction hypothesis of longevity, presenting a dietary pattern far more translational to human practice than extreme caloric or protein restriction regimens. It suggests that while a Mediterranean-style diet is beneficial, optimising its protein and methionine load – favouring plant and fish sources – could further enhance healthspan. Practically, it strengthens the case for time-varying protein intake (perhaps higher around resistance training sessions, lower on rest days) and a general shift towards fish and plant-based protein sources, especially for older adults where mTOR signalling might be a concern.
**Actionable takeaway:** Consider adopting a more plant-forward, fish-inclusive version of the Mediterranean diet. Pay attention to protein source diversity, aiming to reduce excessive intake of high-methionine animal products. If you are lifting weights, strategically time your protein intake to support muscle protein synthesis, but be mindful of overall protein load across the week.
Tyrosine Levels: A New Amino Acid Longevity Biomarker?
**What was found:** A large population analysis revealed that men with higher circulating blood levels of the amino acid tyrosine had significantly shorter lifespans, with an estimated loss of close to one year of life expectancy compared to those with lower levels. While observational, tyrosine stood out as a negative longevity biomarker among the measured amino acids.
**Why it matters:** This opens up a new avenue of inquiry into the role of specific amino acid patterning in mortality risk, extending beyond the more commonly studied branched-chain amino acids. If replicated, tyrosine levels could become a valuable addition to amino acid profiling for assessing cardiovascular and metabolic risk, and general age-related mortality. It also raises intriguing practical questions about high-tyrosine diets or supplementation (sometimes used for cognitive enhancement) in men who might have other underlying risk factors. The typical advice we give on cognitive enhancement protocols has not yet factored in tyrosine as a negative biomarker, so this is definitely something to watch.
**Actionable takeaway:** While it's too early to recommend specific dietary changes based solely on this, if you're undertaking advanced biomarker testing, consider including a comprehensive amino acid profile. If tyrosine levels are elevated, discuss with your health professional whether dietary adjustments or further investigation are warranted.
Primary source: Healthspan Action Coalition
Psilocybin for Neuroplasticity and Brain Ageing in Older Adults
**What was found:** The Berkeley Center for the Science of Psychedelics has initiated recruitment for a clinical trial investigating psilocybin's effects on neuroplasticity and brain ageing markers in adults aged 60–85. Participants will receive 1–30 mg of psilocybin, undergoing MRI scans at three time points: one week before, one week after, and one month after dosing. The study aims to evaluate structural and functional brain changes relevant to ageing, cognition, and emotional processing.
**Why it matters:** This trial directly addresses a crucial question: can classic psychedelics favourably modulate brain ageing trajectories by enhancing neuroplasticity? If psilocybin proves capable of improving network efficiency or default-mode connectivity in older adults, it could emerge as a powerful tool for cognitive resilience and emotional well-being in later life. This research also intersects with sleep and recovery, as psychedelics frequently lead to downstream improvements in sleep architecture and emotional regulation – both vital components of healthy ageing. /legal/disclaimer
**Actionable takeaway:** This is very early-stage research. While promising, psilocybin is a controlled substance and currently illegal for recreational use in the UK. This trial will provide valuable insights, but awaiting clinical translation and regulatory approval is essential before considering such interventions.
Primary source: Berkeley Center for the Science of Psychedelics
NAD+ and NR: An Updated, Nuanced Perspective
**What was found:** Recent human data on NAD+ levels in blood suggest little to no consistent decline with age, challenging previous assumptions largely based on animal models. While trials of nicotinamide riboside (NR) reliably increase NAD+ in specific tissues, they haven't consistently shown clear lifespan extension or significant global biological age reversal. However, some trials do indicate improvements in inflammatory markers.
**Why it matters:** This updated perspective suggests that widespread, blanket NAD+ supplementation may be less foundational than previously marketed, particularly if whole-blood NAD+ levels remain adequate with age. It encourages a more targeted, biomarker-guided approach to NAD+ precursor supplementation. For instance, benefits might be more pronounced in specific indications such as mitochondrial myopathies, certain neurodegenerative risks, or when stacked strategically with sirtuin activators to leverage tissue-specific effects. It also aligns with the organ-specific NAD+ findings from the AI-driven atlas discussed earlier.
**Actionable takeaway:** Re-evaluate your NAD+ precursor strategy. Instead of universal supplementation, consider a more targeted approach if you have specific clinical indications or use advanced biomarker testing to guide decisions. If you are taking NAD+ precursors, ensure you are tracking relevant outcomes beyond just blood NAD levels. For a deeper dive into current evidence, see our article on NAD+ precursors.
Primary source: YouTube (Longevity Science Update) Primary source: Science Focus
Semaglutide and Biological Ageing in Non-HIV Adults
**What was found:** Echoing the findings in the HIV-positive cohort, a separate re-analysis of a 32-week semaglutide trial in adults without HIV (also originally focused on weight and metabolic endpoints) showed that semaglutide was associated with a slower progression of multiple DNA-methylation-based ageing clocks compared to placebo. This supports a more generalisable anti-ageing effect of semaglutide in metabolically unhealthy adults, not just those with HIV.
**Why it matters:** This second independent signal further strengthens the hypothesis that GLP-1 agonists may exert systemic geroprotective effects beyond their well-known impact on glucose regulation and weight. The mechanism appears to involve epigenetic re-programming, suggesting a fundamental modulation of ageing pathways. This is crucial for the long-term risk-benefit assessment of GLP-1s, as it implies potential healthspan gains that go beyond merely preventing cardiometabolic events. It also provides an important benchmark for future trials of rapamycin and senolytics, allowing for direct comparison of their effects on similar epigenetic clocks. For further reading, check our semaglutide deep dive.
**Actionable takeaway:** The consistent signal from semaglutide on epigenetic clocks across different metabolically challenged cohorts is compelling. For individuals with obesity or type 2 diabetes, the potential for an anti-ageing benefit alongside metabolic improvements makes GLP-1s an increasingly attractive therapeutic option. Discuss this with your healthcare provider. /legal/disclaimer
Gaps we are watching
1. **Tissue-specific NAD+ data in humans:** While whole-blood NAD+ may not decline globally, the AI-driven organ map highlights tissue-specific variations. We need more non-invasive or minimally invasive methods to measure NAD+ levels in various human tissues to truly understand where supplementation might be most impactful. 2. **Long-term safety and efficacy of novel PAI-1 inhibitors:** The TM5614 data is exciting, but it's a small, short-term study. We need larger, longer trials to confirm its biological age-reversing effects and assess potential side effects with chronic use. This will be key to moving this class of compounds from experimental to clinical application. 3. **Human data on piceatannol beyond skin health:** While the mouse data for piceatannol is promising regarding senolytic effects in key organs, and the skin health data is interesting, larger human trials specifically assessing systemic ageing biomarkers and functional outcomes are needed to elevate it beyond a 'promising supplement' to a genuinely evidence-backed geroprotector.
Bottom line
This month's roundup underscores a significant shift in longevity science: we are moving beyond simply identifying correlations to actively testing and quantifying the effects of interventions. The consistent signal from GLP-1 agonists on epigenetic clocks is perhaps the most compelling story, suggesting these drugs are far more than just weight-loss tools, with true geroprotective potential. Similarly, the long-term data on resistance training provides clear, actionable guidance on a fundamental healthspan lever. For those seeking a competitive edge, or simply a clearer path to healthy longevity, these insights offer both reassurance regarding established practices and exciting glimpses into future therapeutic frontiers. Focus on the low-hanging fruit: move consistently, eat well, and critically evaluate emerging therapeutics. The evidence base for truly actionable longevity interventions is solidifying rapidly.